Dinobuton is a acaricide, a type of pesticide used to control mites. It is a contact insecticide that affects the nervous system of mites, leading to paralysis and death. Dinobuton is synthesized by a multi-step process that involves the reaction of 2,4-dinitrophenol with 2-methyl-2-propanol. It is applied to crops as a suspension concentrate or an emulsifiable concentrate. Dinobuton is highly effective against a wide range of mite species, including spider mites, rust mites, and broad mites. However, it is also toxic to beneficial insects and can accumulate in the environment, raising concerns about its potential ecological impact. Studies on dinobuton are conducted to evaluate its efficacy and environmental safety. Researchers investigate its impact on non-target organisms, its persistence in soil and water, and its potential for bioaccumulation in food chains. The study of dinobuton is important to understand its benefits and risks, and to develop more sustainable pest control strategies.'
dinobuton: Russian drug; structure
ID Source | ID |
---|---|
PubMed CID | 13783 |
CHEMBL ID | 1358468 |
CHEBI ID | 81914 |
SCHEMBL ID | 14906 |
MeSH ID | M0045957 |
Synonym |
---|
kasebon |
mc 1053 |
epa pesticide chemical code 228700 |
drawinol |
akrex |
isopropyl 2,4-dinitro-6-sec-butylphenyl carbonate |
ent 27,244 |
uc 19786 |
1-methylethyl 2-(1-methylpropyl)-4,6-dinitrophenyl carbonate |
2,4-dinitro-6-sec-butylphenyl isopropyl carbonate |
dinobuton |
isophen (pesticide) |
dessin |
phenol, 2-sec-butyl-4,6-dinitro-, isopropylcarbonate |
carbonic acid, 1-methylethyl 2-(1-methylpropyl)-4,6-dinitrophenyl ester |
dinitro-sec-butylphenyl isopropyl carbonate |
isopropyl-2-(1-methyl-n-propyl)-4,6-dinitrophenyl carbonate |
caswell no. 128f |
carbonic acid, 2-sec-butyl-4,6-dinitrophenyl isopropyl ester |
brn 2065340 |
dinofen |
acrex |
(2-sek.butyl-4,6-dinitrofenyl)-isopropylkarbonat [czech] |
talan |
2-(1-methyl-2-propyl)-4,6-dinitrophenyl isopropylcarbonate |
sytasol |
dinobuton [bsi:iso] |
einecs 213-546-1 |
ds 18302 |
oms 1056 |
ai3-27244 |
2-sec-butyl-4,6-dinitrophenyl isopropyl carbonate |
hsdb 1527 |
union carbide 19786 |
2,4-dinitro-6-sek.butyl-isopropylphenylcarbonat [german] |
CBDIVE_000527 |
NCGC00166186-01 |
(2-butan-2-yl-4,6-dinitrophenyl) propan-2-yl carbonate |
AKOS001766460 |
2-(butan-2-yl)-4,6-dinitrophenyl propan-2-yl carbonate |
STK757852 |
973-21-7 |
C18721 |
2,4-dinitro-6-sek.butyl-isopropylphenylcarbonat |
(2-sek.butyl-4,6-dinitrofenyl)-isopropylkarbonat |
a711xev1pf , |
unii-a711xev1pf |
NCGC00255564-01 |
tox21_302224 |
cas-973-21-7 |
dtxcid2020268 |
dtxsid4040268 , |
propanedioic acid, 1,3-dithiolan-2-ylidene-, bis(1-methylethyl) ester, mixt. with o,o-dimethyl o-(3-methyl-4-(methylthio)phenyl)phosphorothioate |
62655-72-5 |
isothion |
isofen |
carbonic acid-2-sec-butyl-4,6-dinitro-phenyl isopropyl ester |
dinobuton [mi] |
dinobuton [hsdb] |
(rs)-2-sec-butyl-4,6-dinitrophenyl isopropyl carbonate |
dinobuton [iso] |
SCHEMBL14906 |
CHEBI:81914 , |
CHEMBL1358468 |
dinobuton, pestanal(r), analytical standard |
Q1226658 |
AKOS040751588 |
Excerpt | Reference | Relevance |
---|---|---|
"Tests on a culture of embryonal fibroblast cells furnished preliminary data on a possible use of vitamins C, PP, folic acid and methionine in preventing the toxic effects of phosphamide and acrex." | ( [Protective action of vitamins and amino acids against the cytotoxic effect of phosphamide and Acrex]. Dorofeev, VM; Zolotnikova, GP, ) | 0.13 |
Class | Description |
---|---|
C-nitro compound | A nitro compound having the nitro group (-NO2) attached to a carbon atom. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 158.4890 | 0.0032 | 45.4673 | 12,589.2998 | AID2517 |
Chain A, TYROSYL-DNA PHOSPHODIESTERASE | Homo sapiens (human) | Potency | 39.8107 | 0.0040 | 23.8416 | 100.0000 | AID485290 |
hypoxia-inducible factor 1 alpha subunit | Homo sapiens (human) | Potency | 49.2911 | 3.1890 | 29.8841 | 59.4836 | AID1224846; AID1224894 |
RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 20.9348 | 0.0060 | 38.0041 | 19,952.5996 | AID1159521; AID1159523 |
SMAD family member 2 | Homo sapiens (human) | Potency | 20.6831 | 0.1737 | 34.3047 | 61.8120 | AID1346859; AID1346924 |
SMAD family member 3 | Homo sapiens (human) | Potency | 20.6831 | 0.1737 | 34.3047 | 61.8120 | AID1346859; AID1346924 |
GLI family zinc finger 3 | Homo sapiens (human) | Potency | 21.6899 | 0.0007 | 14.5928 | 83.7951 | AID1259369; AID1259392 |
AR protein | Homo sapiens (human) | Potency | 24.6883 | 0.0002 | 21.2231 | 8,912.5098 | AID1259243; AID1259247; AID743035; AID743036; AID743042; AID743053; AID743054; AID743063 |
estrogen receptor 2 (ER beta) | Homo sapiens (human) | Potency | 19.7516 | 0.0006 | 57.9133 | 22,387.1992 | AID1259377; AID1259378 |
nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 54.8284 | 0.0010 | 22.6508 | 76.6163 | AID1224838; AID1224839; AID1224893 |
glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 58.2929 | 0.0002 | 14.3764 | 60.0339 | AID720691; AID720692 |
retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 35.7474 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552; AID1159555 |
retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 3.6442 | 0.0008 | 17.5051 | 59.3239 | AID1159527; AID1159531 |
estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 20.4486 | 0.0015 | 30.6073 | 15,848.9004 | AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403 |
farnesoid X nuclear receptor | Homo sapiens (human) | Potency | 8.8450 | 0.3758 | 27.4851 | 61.6524 | AID743217; AID743220 |
pregnane X nuclear receptor | Homo sapiens (human) | Potency | 61.1306 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982 |
estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 41.4139 | 0.0002 | 29.3054 | 16,493.5996 | AID1259244; AID1259248; AID1259383; AID743069; AID743075; AID743077; AID743078; AID743079; AID743080; AID743091 |
peroxisome proliferator-activated receptor delta | Homo sapiens (human) | Potency | 12.6695 | 0.0010 | 24.5048 | 61.6448 | AID743212; AID743215 |
peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 6.4614 | 0.0010 | 19.4141 | 70.9645 | AID743094; AID743140; AID743191 |
vitamin D (1,25- dihydroxyvitamin D3) receptor | Homo sapiens (human) | Potency | 25.4435 | 0.0237 | 23.2282 | 63.5986 | AID743222; AID743223; AID743241 |
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 61.1306 | 0.0017 | 23.8393 | 78.1014 | AID743083 |
activating transcription factor 6 | Homo sapiens (human) | Potency | 8.7076 | 0.1434 | 27.6121 | 59.8106 | AID1159516 |
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a | Homo sapiens (human) | Potency | 54.9410 | 19.7391 | 45.9784 | 64.9432 | AID1159509 |
v-jun sarcoma virus 17 oncogene homolog (avian) | Homo sapiens (human) | Potency | 43.6412 | 0.0578 | 21.1097 | 61.2679 | AID1159526 |
vitamin D3 receptor isoform VDRA | Homo sapiens (human) | Potency | 11.2202 | 0.3548 | 28.0659 | 89.1251 | AID504847 |
thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 28.0331 | 0.0003 | 23.4451 | 159.6830 | AID743065; AID743067 |
heat shock protein beta-1 | Homo sapiens (human) | Potency | 36.7803 | 0.0420 | 27.3789 | 61.6448 | AID743210; AID743228 |
nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 8.1654 | 0.0006 | 27.2152 | 1,122.0200 | AID743202; AID743219 |
nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 35.4813 | 0.0079 | 8.2332 | 1,122.0200 | AID2546; AID2551 |
Voltage-dependent calcium channel gamma-2 subunit | Mus musculus (house mouse) | Potency | 27.3060 | 0.0015 | 57.7890 | 15,848.9004 | AID1259244 |
Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 41.5346 | 0.0023 | 19.5956 | 74.0614 | AID651631; AID720552 |
Glutamate receptor 2 | Rattus norvegicus (Norway rat) | Potency | 27.3060 | 0.0015 | 51.7393 | 15,848.9004 | AID1259244 |
ATPase family AAA domain-containing protein 5 | Homo sapiens (human) | Potency | 21.6899 | 0.0119 | 17.9420 | 71.5630 | AID651632 |
Ataxin-2 | Homo sapiens (human) | Potency | 21.6899 | 0.0119 | 12.2221 | 68.7989 | AID651632 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | 2014 | Journal of biomolecular screening, Jul, Volume: 19, Issue:6 | A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum. |
AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | |||
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 7 (70.00) | 18.7374 |
1990's | 1 (10.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (10.00) | 24.3611 |
2020's | 1 (10.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (20.72) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 14 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |